UNITED STATES - Pharmaceutical companies have now been in the process to produce COVID-19 antiviral pills that aimed to target coronavirus while avoiding the possible side effects as the need for more timely treatment has still been.
Merck & Co and Pfizer Inc, the American multinational pharmaceutical companies, has been preparing to report clinical trial results for experimental COVID-19 antiviral pills. At the same time, their competitors, Novartis AG, Enanta Pharmaceuticals, Pardes Biosciences and Shionogi & Co., Ltd, have been preparing to prove their oral treatments to be more potent and convenient.
Pfizer and Merck, as well as partners Roche AG and Atea Pharmaceuticals, have said that their COVID-19 antiviral pills have been seeking emergency approval this year. Shionogi has intended to start large-scale clinical trials by year-end. Pardes began an early-stage test last month, whereas Enanta has aimed to start human trials next year at the earliest. On the other hand, Novartis has been testing its pill on animals.
